Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is one of the best drug stocks to buy according to analysts.
Kiniksa Pharmaceuticals International Plc (KNSA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 3,999,800 | $255,787,210 | +7% | 2.35% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,834,643 | $181,275,420 | +1% | 0.91% |
| 3. | Tang Capital Management Kevin C. Tang | 2,259,889 | $144,519,902 | 6.56% | |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 957,514 | $61,233,020 | +8% | 0.03% |
| 5. | Spruce Street Capital Alex Rosen And Simon Basseyn | 918,070 | $58,710,577 | +21% | 11.52% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.24 | 235,019 | $4,520,942.99 | 843,352 | 2018-05-29 | Filing | |
| $20.91 | 25,000 | $522,747.50 | 608,333 | 2018-05-29 | Filing | |
| $19.81 | 250,000 | $4,953,150.00 | 583,333 | 2018-05-29 | Filing | |
| $18.00 | 333,333 | $5,999,994.00 | 333,333 | 2018-05-29 | Filing | |
| $18.00 | 69,444 | $1,249,992.00 | 900,443 | 2018-05-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $81.43 | 3,673 | $299,092.39 | 11,672 | 2026-07-29 | Filing | |
| $54.04 | 21,097 | $1,140,081.88 | 65,623 | 2026-05-01 | Filing | |
| $53.52 | 37,327 | $1,997,741.04 | 86,720 | 2026-05-01 | Filing | |
| $54.02 | 48,565 | $2,623,481.30 | 0 | 2026-05-01 | Filing | |
| $54.01 | 2,141 | $115,635.41 | 0 | 2026-04-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,971,361 | $445,818,527 | 0.02% | |
| 2. | 2,739,615 | $175,198,378 | 0% | |
| 3. | 1,911,335 | $122,229,873 | 0.01% | |
| 4. | 1,360,840 | $87,025,718 | 0% | |
| 5. | 1,011,143 | $64,662,626 | 0% |
News See All
9 Best Drug Stocks to Buy According to Analysts
On April 27, Jurrien Timmer, director of global macro at Fidelity Investments, appeared on CNBC to talk about the market and oil prices, and how necessary it is for oil prices to retreat from their highs...
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript February 24, 2026Kiniksa Pharmaceuticals, Ltd. misses on earnings expectations.
Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)
On December 12, Wells Fargo analyst Eva Fortea Verdejo indicated her bullish sentiment and assigned a Buy rating to Kiniksa Pharmaceuticals International (NASDAQ:KNSA).
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Kiniksa Pharmaceutical Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals First Quarter 2025 Earnings Conference Call.
10 Best UK Growth Stocks to Buy Now
The start of this year has marked interesting developments for the UK market.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Hedge Fund Resource Center